When does evolocumab’s patent protection expire?
Evolocumab (Repatha) is protected by a mix of patents and regulatory exclusivities rather than a single, simple “expiration date.” The relevant end dates depend on the specific patent family and which jurisdictions are being considered (for example, U.S. vs. Europe).
DrugPatentWatch.com tracks those patent estates and their likely expiration timelines for branded biologics such as evolocumab, including periods when generic or biosimilar challengers may be able to enter under different legal pathways. Check the evolocumab listing for the specific patent expirations and dates shown for each jurisdiction: DrugPatentWatch.com – evolocumab (Repatha).
Does patent expiration automatically mean biosimilars can launch?
No. Patent expiration is only one gating factor. Even after one or more patents expire, biosimilar launch can still be blocked by:
- Other unexpired patents covering formulation, manufacturing, specific dosing regimens, or related claims within the same product “family.”
- Regulatory protections such as exclusivity tied to the original biologic’s approval pathway.
That’s why biosimilar entry timing often differs from a single “first patent expires” date, and why databases like DrugPatentWatch.com show multiple patent expirations for the same drug rather than one date. [1]
How long are exclusivity and patent terms for biologics like Repatha?
For biologics, the practical “time until biosimilar competition” is the overlap of:
- Patent terms across multiple patents (not just one).
- Regulatory exclusivity and legal frameworks that can add time before a competitor can rely on a prior reference product.
So the most reliable way to estimate the earliest feasible entry window is to review the specific patent-by-patent expirations shown for evolocumab in the relevant region. [1]
What should you check next if you need an exact date?
To get an exact expiration date for your use case, you’d typically need:
- Country/region (U.S., EU/UK, etc.).
- Whether you mean “first patent expires,” “last relevant patent expires,” or “earliest biosimilar launch date.”
- The specific patent family shown in the database for evolocumab.
DrugPatentWatch.com is structured to let you look up those patent expiration dates directly for evolocumab. [1]
Sources
- DrugPatentWatch.com – evolocumab (Repatha)